Breakthrough In Indexing Set To Deliver Drug Literature In Half the Time
Elsevier’s Emscopes to launch in 2007 with 'Drug-Specific Indexing'
Amsterdam, The Netherlands, 22 January, 2007 – Today Elsevier announced it has developed a new method for indexing full-text information about individual drugs. The new technique will significantly reduce the time pharmaceutical companies have to spend keeping up-to-date with research about their own and competing products. The benefits of ‘Drug-Specific Indexing’ will be evident in Elsevier’s forthcoming service Emscopes™.
A new kind of online product literature database, Emscopes promises to combine tailored content selected for each customer, with Elsevier’s new standard drug-specific indexing process and a simple search interface. Available from February 2007, Emscopes will provide up-to-date, instant and comprehensive reports of the research literature on any drug.
The 'Drug-Specific Indexing' goes deep into the full text of every article to extract detailed information for each drug, such as adverse drug reactions, drug comparisons, administration routes and dosage. Bringing together this data in Emscopes, means that anyone in the company – from Medical Advisors to Drug Safety to Sales & Marketing – will effectively have the full-text read and summarised for them.
Martin O’Malley, Managing Director of Elsevier’s corporate division says "for decades Elsevier has provided top-quality abstracting and indexing services to the pharmaceutical market. EMBASE for example is renowned for its superior drug indexing and the EMTREE thesaurus, and is used by clinical researchers in virtually every major pharmaceutical company in the world. We now plan to deliver an ‘off-the-shelf’ solution for companies to monitor the relevant published research at an extraordinary level of accuracy."
Senior Product Manager, Tessa Sterkenburg, explains Elsevier’s thinking behind the technology: "We have a team of people reading the full-text to extract relevant drug information. Now that this is embedded in our regular indexing we can process new records very quickly to give the utmost currency, and we can offer the highest precision indexing cost-effectively."
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com
+31 20 485 3542